Australian Brands-Aspen Pharmacare-Australian Drugs-Glaxosmithkline

GSK sells Australian drugs to Aspen for $270 mln

A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company results

JOHANNESBURG/LONDON (Reuters) - GlaxoSmithKline advanced its clear-out of non-core drugs on Wednesday with a deal to sell 25 older brands marketed in Australia to South Africa's Aspen Pharmacare for 172 million pounds. Andrew Witty, chief executive of Britain's biggest drugmaker, said last month during quarterly results that he was looking for further ways to simplify the GSK business, following previous divestments in consumer health. The old Australian brands being bought by Aspen include herpes treatment Valtrex, epilepsy drug Lamictal and the antibiotic Amoxil. ... read more..

source:http://yhoo.it/Ovc9K4

Food And Drug Administration-Meningococcal Disease-Bacterial Meningitis-Glaxosmithkline Plc

U.S. approves Glaxo meningitis vaccine for children

A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company results

WASHINGTON (Reuters) - U.S. regulators on Thursday approved a new children's vaccine from GlaxoSmithKline PLC that targets two common causes of bacterial meningitis, which can be fatal. The U.S. Food and Drug Administration said the vaccine, MenHibrix, is meant for children aged six weeks to 18 months and combines vaccines for meningococcal disease and Hib disease. The diseases are common causes of the infection. The FDA had rejected MenHibrix twice before, in 2010 and 2011, but GlaxoSmithKline said it had resolved regulators' questions about the vaccine's potency and efficacy. ... read more..

source:http://yhoo.it/MW5qWP

Food And Drug Administration-Restless Legs Syndrome-Glaxosmithkline-Xenoport-Gsk

U.S. approves GSK, Xenoport drug for new use

A GlaxoSmithKline logo is seen outside one of its buildings in west London

LONDON (Reuters) - GlaxoSmithKline and XenoPort have received approval from the U.S. Food and Drug Administration to sell Horizant to treat post-herpetic neuralgia, the companies said on Thursday. The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $10 million from GSK following first sales of the drug in its new use. (Reporting by Ben Hirschler; editing by Kate Kelland) read more..

source:http://yhoo.it/KWnDD2